These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28474830)

  • 1. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained? Authors' reply.
    Strik AS; D'Haens GR
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1474-1475. PubMed ID: 28474830
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained?
    Bar-Yoseph H; Chowers Y
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1473-1474. PubMed ID: 28474829
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 May; 43(9):1017-8. PubMed ID: 27040167
    [No Abstract]   [Full Text] [Related]  

  • 7. Not all tumour necrosis is granular necrosis: authors' response.
    Fuchs TL; Chou A; Ahadi M; Sheen A; Sioson L; Mittal A; Samra J; Gill AJ
    Pathology; 2023 Oct; 55(6):904-906. PubMed ID: 37544876
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Eberhardson M; Söderling JK; Olén O
    Aliment Pharmacol Ther; 2018 Jan; 47(1):147-148. PubMed ID: 29226402
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Felwick R; Cummings JRF
    Aliment Pharmacol Ther; 2017 May; 45(10):1370-1371. PubMed ID: 28417492
    [No Abstract]   [Full Text] [Related]  

  • 10. Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha).
    McLaughlin PJ; Elwood NJ; Russell SM; Andrew SM; McKenzie IF
    Anticancer Res; 1992; 12(4):1243-6. PubMed ID: 1503416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Roblin X; Nancey S; Paul S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1319-1320. PubMed ID: 34029416
    [No Abstract]   [Full Text] [Related]  

  • 12. Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release.
    Vossen AC; Tibbe GJ; Buurman WA; Benner R; Savelkoul HF
    Eur Cytokine Netw; 1996 Dec; 7(4):751-5. PubMed ID: 9010677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply.
    Levesque BG; Feagan BG
    Aliment Pharmacol Ther; 2014 Jul; 40(1):121-2. PubMed ID: 24903437
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply: Treatment of refractory neurosarcoidosis with tumour necrosis factor inhibitors--what lies ahead?
    Pereira JA; Anderson NE
    Intern Med J; 2012 Apr; 42(4):478-9. PubMed ID: 22498131
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
    Ding NS; Malietzis G; Hart AL
    Aliment Pharmacol Ther; 2018 Jan; 47(1):142-143. PubMed ID: 29226405
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-tumour necrosis factor-alpha therapies in Crohn's disease.
    Sprakes MB; Hamlin PJ
    Br J Hosp Med (Lond); 2009 Nov; 70(11):644-7. PubMed ID: 20081592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism.
    Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA
    Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab.
    Hassan C; Ierardi E; Burattini O; De Francesco V; Zullo A; Stoppino G; Panella C; Morini S
    Dig Liver Dis; 2007 Sep; 39(9):811-7. PubMed ID: 17652038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Authors' response.
    Turner D; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.